secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2026-06-12T20:30:17+00:00
Accession:  0001193125-26-269549
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Definium shareholders approve 5M share increase in equity plan, re-elect directors
--------------------------------------------------------------------------------

- Shareholders approved amendment to 2025 Equity Incentive Plan, increasing shares by 5,000,000 to 9,500,000 total.
- All seven director nominees elected: Barrow, Bruhn, Crystal, Gryska, Krebs, Vallone, Adsett.
- Appointment of KPMG LLP as independent auditor approved for fiscal year until 2027 annual meeting.
- Quorum of 78,673,592 shares (approx. 72% of outstanding) was present at the June 11, 2026 meeting.
- Equity Plan Amendment effective immediately upon shareholder approval at the Annual Meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526269549/0001193125-26-269549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526269549/dftx-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-269549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer